These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Life insurance for the HIV-positive applicant--are we there yet? MacKenzie R J Insur Med; 2008; 40(2):93-9. PubMed ID: 19119587 [No Abstract] [Full Text] [Related]
25. ASPD blunts the effects of HIV and antiretroviral treatment on event-related brain potentials. Bauer LO; Shanley JD Neuropsychobiology; 2006; 53(1):17-25. PubMed ID: 16319505 [TBL] [Abstract][Full Text] [Related]
26. Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient. Lee DH; Malat GE; Bias TE; Harhay MN; Ranganna K; Doyle AM Transpl Infect Dis; 2016 Aug; 18(4):625-7. PubMed ID: 27159656 [TBL] [Abstract][Full Text] [Related]
27. HIV testing and treatment among at-risk drinking injection drug users. Arasteh K; Des Jarlais DC J Int Assoc Physicians AIDS Care (Chic); 2009; 8(3):196-201. PubMed ID: 19414827 [TBL] [Abstract][Full Text] [Related]
28. High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. Yotebieng M; Edmonds A; Lelo P; Wenzi LK; Ndjibu PT; Lusiama J; Kabuayi JP; Behets F AIDS; 2015 Sep; 29(15):2055-7. PubMed ID: 26352882 [TBL] [Abstract][Full Text] [Related]
29. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings? Rowe KA; Makhubele B; Hargreaves JR; Porter JD; Hausler HP; Pronyk PM Int J Tuberc Lung Dis; 2005 Mar; 9(3):263-9. PubMed ID: 15786888 [TBL] [Abstract][Full Text] [Related]
30. Idiopathic intracranial hypertension associated with anaemia, secondary to antiretroviral drug in a human immunodeficiency virus positive patient. Ananth JV; Sudharshan S; Selvakumar A; Devaleenal BJ; Kalaivani K; Biswas J Indian J Ophthalmol; 2018 Jan; 66(1):168-169. PubMed ID: 29283154 [TBL] [Abstract][Full Text] [Related]
31. Pseudo-Gaucher cells in disseminated mycobacterial infection. Busarla SV; Sadruddin FA; Sohani AR Am J Hematol; 2013 Feb; 88(2):155. PubMed ID: 22307983 [No Abstract] [Full Text] [Related]
32. The obligation to provide antiretroviral treatment in HIV prevention trials. Lo B; Padian N; Barnes M AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698 [TBL] [Abstract][Full Text] [Related]
33. Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Yiu P; Nguyen NN; Holodniy M Pharmacotherapy; 2011 May; 31(5):480-9. PubMed ID: 21923429 [TBL] [Abstract][Full Text] [Related]
34. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients. Evidence from the ICONA cohort. Merito M; Pezzotti P; Eur J Health Econ; 2006 Mar; 7(1):30-6. PubMed ID: 16404620 [TBL] [Abstract][Full Text] [Related]
35. Perceived Family Support and Antiretroviral Adherence in HIV-Positive Individuals: Results from a Community-Based Positive Living With HIV Study. Poudel KC; Buchanan DR; Amiya RM; Poudel-Tandukar K Int Q Community Health Educ; 2015; 36(1):71-91. PubMed ID: 26525224 [TBL] [Abstract][Full Text] [Related]
36. An assessment of adverse effects of antiretroviral therapy on the development of HIV positive children by observation of dental mineralization chronology. Trigueiro M; Tedeschi-Oliveira SV; Melani RF; Ortega KL J Oral Pathol Med; 2010 Jan; 39(1):35-40. PubMed ID: 20359308 [TBL] [Abstract][Full Text] [Related]
37. A longitudinal evaluation of a social support model of medication adherence among HIV-positive men and women on antiretroviral therapy. Simoni JM; Frick PA; Huang B Health Psychol; 2006 Jan; 25(1):74-81. PubMed ID: 16448300 [TBL] [Abstract][Full Text] [Related]